Intravascular ultrasound developer EndoSonics last month signed an agreement to acquire Navius, a privately held San Diego-based developer of angioplasty balloons, stents, and intravascular radiation devices. The Navius acquisition gives EndoSonics
Intravascular ultrasound developer EndoSonics last month signed an agreement to acquire Navius, a privately held San Diego-based developer of angioplasty balloons, stents, and intravascular radiation devices. The Navius acquisition gives EndoSonics access to the intravascular ultrasound-guided stenting market. EndoSonics has agreed to pay approximately $15.5 million in cash and EndoSonics common stock, in addition to royalties on future product sales. The deal was expected to close July 31.
The Rancho Cordova, CA, firm also announced last month an agreement in principle to partner with Fukuda Denshi, a Japanese medical products company. Fukuda has agreed to make an equity investment and R&D funding totaling $13 million in EndoSonics.
The agreements cut EndoSonics' final ties to Johnson & Johnson's Cordis division, the company's former distributor and therapeutic product partner. EndoSonics decided to terminate its relationship with Cordis when its product orders declined (SCAN 4/29/98).
In other EndoSonics news, the company reported second-quarter 1998 (end-June) net income of $1 million on revenue of $10 million, a 34% increase over the $751,000 net income on revenue of $7.1 million for the previous year's second quarter.
GE HealthCare Debuts AI-Powered Cardiac CT Device at ACC Conference
April 1st 2025Featuring enhanced low-dose image quality with motion-free images, the Revolution Vibe CT system reportedly facilitates improved diagnostic clarity for patients with conditions ranging from in-stent restenosis to atrial fibrillation.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
GE HealthCare Debuts AI-Powered Cardiac CT Device at ACC Conference
April 1st 2025Featuring enhanced low-dose image quality with motion-free images, the Revolution Vibe CT system reportedly facilitates improved diagnostic clarity for patients with conditions ranging from in-stent restenosis to atrial fibrillation.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
2 Commerce Drive
Cranbury, NJ 08512